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Abstract Breast cancer is one of the most prevalent cancer
types among women. The use of magnetic fluids for specific
delivery of drugs represents an attractive platform for chemo-
therapy. In our previous studies, it was demonstrated that
maghemite nanoparticles coated with rhodium (II) citrate
(Magh-Rh2Cit) induced in vitro cytotoxicity and in vivo anti-
tumor activity, followed by intratumoral administration in
breast carcinoma cells. In this study, our aim was to follow
intravenous treatment to evaluate the systemic antitumor ac-
tivity and toxicity induced by these formulations in Balb/c
mice bearing orthotopic 4T1 breast carcinoma. Female Balb/c
mice were evaluated with regard to toxicity of intravenous
treatments through analyses of hemogram, serum levels of
alanine aminotransferase, iron, and creatinine and liver, kid-
ney, and lung histology. The antitumor activity of rhodium (II)
citrate (Rh2Cit), Magh-Rh2Cit, and maghemite nanoparticles
coated with citrate (Magh-Cit), used as control, was evaluated
by tumor volume reduction, histology, and morphometric
analysis. Magh-Rh2Cit and Magh-Cit promoted a significant
decrease in tumor area, and no experimental groups presented
hematotoxic effects or increased levels of serum ALT and
creatinine. This observation was corroborated by the histo-
pathological examination of the liver and kidney of mice.
Furthermore, the presence of nanoparticles was verified in
lung tissue with no morphological changes, supporting the
idea that our nanoformulations did not induce toxicity effects.
No studies about the systemic action of rhodium (II) citrate-
loaded maghemite nanoparticles have been carried out, mak-
ing this report a suitable starting point for exploring the
therapeutic potential of these compounds in treating breast
cancer.
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Introduction
Breast cancer is the most common type of cancer among
women (excluding non-melanoma skin cancer) in both devel-
oped and developing countries [1]. Conventional treatments
include surgery, radiotherapy, chemotherapy, and hormone
therapy, and their effectiveness depends on the progress and
type of the tumor [2, 3]. However, breast cancer remains one of
the world’s most devastating diseases, with more than 458,000
deaths and 1.38 million new cases each year [4, 5]. Chemo-
therapy, which is a common therapeutic approach, is used in
high doses due to its lack of specificity to tumor cells, with
consequent high systemic toxicity [6].
Therefore, the development of therapeutic strategies to se-
lectively deliver drugs to the tumor, with no toxic effects on
healthy tissues, represents an attractive area for breast cancer
treatment. Among them, nanotechnology has been indicated as
a new approach for cancer treatment over the past decade. It is
starting to be used to develop imaging agents and nanosensors
that detect biological signs of cancer and nanoparticles (NPs)
that target cancerous cells with drugs [8]. The latter direction
represents progress in relation to traditional therapies, since it
would reduce systemic toxicity, thanks to the higher efficiency
of drug delivery in chemotherapy. Indeed, superparamagnetic
nanoparticles (SPIOs) mediating drug delivery, for instance, are
used to target and accumulate drug molecules in the tumor,
increasing the effectiveness of chemotherapy [7–9].
The small size of SPIOs has an influence on the passive
transport of drugs through the tumor vessels and determines the
speed at which they are removed by the reticuloendothelial
system (RES). Firstly, SPIOs may have good physiological
tolerance if they are functionalized with hydrophilic agents,
preventing the opsonization by plasma protein [10–12]. Sec-
ond, tumors larger than 2 mm3 have an increased demand for
blood, resulting in the process of angiogenesis and leaky vas-
culature with 100–800-nm pores, larger than those found in
healthy blood vessels [8]. This defective architecture impairs
lymphatic drainage near the tumor, increasing the enhanced
permeability and retention (EPR) effect of SPIOs in the tumor
[13, 14]. Finally, SPIO-mediated drug delivery has the potential
to enhance drug bioavailability, improve the time release of
drug molecules, and enable precision drug targeting. It repre-
sents progress in relation to traditional therapies by reducing the
systemic toxicity [7–9, 12, 15–17].
A variety of SPIOs coated with chemotherapy agents, in-
cluding some inorganic compounds such as cisplatin and
carboplatin, have been studied [18, 19]. Free rhodium (II)
citrate (Rh2Cit) is also an inorganic and antitumor compound
[20], which has been successfully stabilized by maghemite NPs
[21]. Moreover, Rh2Cit presents hydrophilic groups, which
improve its internalization by tumor cells and reduce the uptake
by the RES [22].
Our research group has demonstrated that Rh2Cit and rho-
dium (II) citrate-loaded maghemite nanoparticles (Magh-
Rh2Cit) induced significant cytotoxic effects on 4T1 and
MCF-7 breast cancer cell lines. Moreover, these formulations
reduced orthotopic 4T1 metastatic mammary carcinoma by
intratumoral administration in Balb/c mice [23, 24]. Local
injection therapy as intratumoral drug administration is com-
monly used for studying drug efficacy against non-metastatic
tumors [25]. It results in less non-specific cytotoxic activity than
with systemic treatments, which can induce adverse effects
[26]. However, it is important to investigate the effect of the
treatments by intravenous administration (i.v.), since this is one
of the routes more frequently used in clinical treatment against
breast metastatic cancer [6, 27]. Furthermore, no studies on the
systemic action of Rh2Cit and Magh-Rh2Cit have been carried
out, making this report a suitable starting point for exploring the
therapeutic potential of these compounds in treating breast
cancer.
Thus, we aimed to investigate the effect of systemic treat-
ment with Rh2Cit and Magh-Rh2Cit on Balb/c mice bearing
4T1 mammary carcinoma. Maghemite nanoparticles coated
with citrate (Magh-Cit) were used as control. The 4T1 cell line
is suitable as an experimental animal model since it develops
metastasis spontaneously from primary tumor, similar to human
breast cancer, and also enables a rapid orthotopic tumor growth
in Balb/c mice [28]. Moreover, the orthotopic model is appro-
priate for understanding the interaction of the drug with the
tumor in its original microenvironment, being useful to recog-
nize how cancer cells respond to the immune system, blood,
hormones, and growth factors [29, 30]. For this purpose, the use
of NPs (Magh-Rh2Cit and Magh-Cit) could improve drug
delivery to the tumor to make the most effective cancer treat-
ment [8, 9, 11, 22].
Materials and methods
Animals and procedures
A total number of 40 Balb/c female mice (12 weeks old) were
purchased from the Multidisciplinary Center for Biological
Investigation in Laboratory Animal Science (Cemib) of the
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State University of Campinas (Unicamp, SP/Brazil). All mice
were maintained in plastic cages under standard conditions of
12-h dark/light cycle. The animals, weighing at the beginning
of the experiment 21.83±1.52 g, were fed with standard diet
and water ad libitum.
Mice were evaluated with regard to the treatments’ toxicity
through analyses of blood, liver, kidney, and lung histology. In
addition, the antitumor activity of rhodium (II) citrate and
maghemite nanoparticles coated with rhodium (II) citrate
was verified by tumor volume reduction, morphometry, and
histology. All experiments described were approved by the
Animal Research Ethics Committee of the University of
Brasilia–Institute of Biologic Sciences, Brazil (UnBDOC no.
109434/2008).
Preparation of the rhodium (II) citrate and rhodium (II)
citrate-loaded maghemite nanoparticles
All formulations (Rh2Cit, Magh-Rh2Cit and Magh-Cit) were
prepared and characterized as previously described [23, 24].
Magh-Cit was used as control of NPs without rhodium. Brief-
ly, Rh2Cit was synthesized by exchanging trifluoroacetate
ligands from the precursor rhodium (II) trifluoroacetate with
citrate ligands. The compound was obtained as a green aque-
ous solution with a standardized concentration of 0.054mol/L.
Maghemite nanoparticles were synthesized by alkaline co-
precipitation of Fe2+ and Fe3+ ions [31]. The particles obtained
in the magnetite (Fe3O4) phase were oxidized to maghemite
(γ-Fe2O3) by bubbling of oxygen gas and were subsequently
purified by dialysis with deionized water for several days
([Fe]=0.37 M). The Magh-Rh2Cit was prepared using 5 mL
of the colloidal dispersion with 1 mL of Rh2Cit and stirred for
24 h.
Orthotopic tumor cell implantation and treatment
The 4T1 breast carcinoma cells were thawed and cultivated in
flasks with Dulbecco’s modified Eagle’s medium (DMEM)
(Sigma, St. Louis, MO) supplemented with 1 % penicillin and
10 % fetal bovine serum (FBS) at 37 °C in a humidified
atmosphere with 5 % CO2. One week later, Balb/c mice were
anesthetized with ketamine (80 mg/kg) and xylazine
(10 mg/kg) by intraperitoneal route. Then, 2×104 4T1 cells
(in suspension in 50 μL serum-free DMEM) were injected
(1-mL-gauge needle) in their left mammary gland, which is
the natural primary microenvironment of breast tumor
occurrence.
Seven days after implantation of 4T1 cells, mice bearing
tumor were distributed into four experimental groups (n=8/
group), and each group was treated with 50 μL of (1) Rh2Cit,
(2) Magh-Rh2Cit, (3)Magh-Cit, or (4) water (solution solvent,
control group). Treatments were carried out every 4 days by
i.v. injection in the animal’s tail vein, totalizing three
applications of 0.5 mg/kg rhodium (II) citrate for each one
(total dose of Rh2Cit was 1.5 mg/kg). Mice treated with
Magh-Cit received the same iron concentration and nanopar-
ticle amount found in Magh-Rh2Cit (14 mg/kg and 2.4×10
15
particles). It were also included animals without tumor
(healthy, n=8) for comparison with other groups exhibiting
tumor.
During the experiments, deaths were registered for all mice
bearing tumor, leaving at least five animals per group. Thus,
three or five mice were used in each group for the following
analysis. On the 19th day after tumor implantation, 4 days
after the last treatment, mice were anesthetized as previously
described, and blood samples (1 mL/animal) were collected
by cardiac puncture to carry out hemogram and biochemical
dosages of alanine aminotransferase (ALT), creatinine and
serum iron. The animals were then immediately euthanized
by cervical dislocation, according to the American Veterinary
Medical Association (AVMA) guidelines for euthanasia [32].
Then tumor, liver, kidney, and lung were collected to perform
antitumor and systemic toxicity analysis as described below.
Tumor regression
Tumors were surgically removed, their width and length were
measured by a digital pachymeter (Stainless, Hardened), and
the tumor volume was calculated according to the formula
length×width2×0.52 [33]. The tumor regression in experi-
mental groups was evaluated by the tumor’s volume, histopa-
thology, and morphometry.
Tumors were fixed in 4 % paraformaldehyde diluted in
phosphate-buffered saline (PBS) for 4 hours at room temper-
ature, transferred to 70 % ethanol, included in paraffin using
an automatic tissue processor (OMA® DM-40, São Paulo,
Brazil), cut to 5 μm of thickness in a Leica RM2235 manual
microtome (Leica Microsystems, Nussloch, Germany) and
stained with hematoxylin-eosin (HE) for histological analyses
(light microscopy), in order to verify cell proliferation pattern,
pleomorphism, degree of cell differentiation, and cell death.
Morphometric analysis was also carried out to verify the
percentage of coagulation necrosis for each treatment. Necro-
sis areas were measured as adapted from our previous reports
[8, 37], with a total of three sections (20 μm far) for each
tumor collected from five mice per group.
Systemic toxicity analysis in mice bearing 4T1 breast cancer
after intravenous injection of compounds
In order to evaluate potential systemic toxicity induced by the
treatments, clinical, histology and blood analyses were per-
formed. Treated mice were continuously monitored for toxic-
ity indexes such as weight loss, diarrhea, skin ulcers, and
deaths; the time of animal death was recorded throughout
the experimental period.
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Hemogram was processed in a multiple automated hema-
tology analyzer (XZ 2100 Sysmex equipment), and serum
biochemical analyses were run on the automated chemistry
analyzer ADVIA 2400 (Siemens), using the appropriate
Advia chemistry reagents, protocols, and controls.
Histopathology analysis of the liver, kidneys, and lungs
was also performed in order to verify possible toxic effects
induced by treatments. For this, tissues were fixed in
Davidson’s solution for 24 h at room temperature, transferred
to 70 % ethanol, and processed for histology as described
above for tumors.
Possible histopathological alterations in the liver were ver-
ified and quantified thoughmorphometry, using the histopath-
ological alteration index (HAI) [34]. They were classified as
progressive stages for the deterioration of organ functions: I
(do not compromise the functioning of the organ), II (severe,
affecting normal body functions), and III (very severe and
irreversible). A value of HAI was calculated for each group of
animals using the formula HAI= (1×ΣI)+ (10×ΣII)+
(100×ΣIII). Since I, II, and III correspond to the number of
stages of change, the mean HAI was divided into five catego-
ries: 0–10=normal tissue; 11–20=mild to moderate damage
to the tissue; 21–50=moderate to severe damage to the tissue;
51–100=severe damage to the tissue; and greater than 100=
irreparable damage to the tissue. A morphometric model [35,
36] was also applied to obtain the volume, area, and diameter
parameters of hepatocytes. Images of liver histopathological
sections of three animals in each group were made with ×40
objective lens, resulting in nine images per group.Measures of
ten hepatocytes for each image were performed using Image
Pro-Plus 6.0 software (Media Cybernetics, Silver Spring,
USA/Microsoft® Windows 32-bit Systems Window® XP
Vista). The volumetric measurements were estimated, consid-
ering the hepatocytes as a sphere with a volume V=4/3πR3
where the calculation of the radius (R) was given by the
formula A=πR2 [37].
Statistical analysis
Statistical analysis was carried out using SPSS (Statistical Pack-
age for the Social Sciences) version 15.0. Data were expressed
as mean±SEM (standard error of mean) and values of p<0.05
were considered statistically significant. The continuous vari-
ables were tested for normal distribution with the Shapiro-Wilk
test. Differences among the analyzed groups were investigated
through ANOVA when the data were normally distributed or
through Kruskal-Wallis test in order to identify statistical differ-
ence when data were not normally distributed. For significant
ANOVA and Kruskal-Wallis results, Bonferroni post-test and
Mann-WhitneyU test were respectively used to carry out 2-by-2
comparisons between the treatments. For significant Kruskal-
Wallis results, Mann-Whitney U test was performed to verify
differences between the treatments (2-by-2 comparisons).
For the morphometric analysis of the liver, differences
among groups were checked by ANOVA followed by the
Tukey test, using the PDFWord Count & Frequency Statistics
Software 7.0. Values of p<0.05 were considered statistically
significant.
Results and discussion
Tumor dimensions and morphometry
We verified that the tumor growth inhibition in the treatments
with Rh2Cit, Magh-Rh2Cit, and Magh-Cit was about 45, 54,
and 58 %, respectively (Fig. 1a). Although these rates were
statistically non-significant compared to the control group, the
treatments with Magh-Rh2Cit and Magh-Cit also promoted a
significant decrease in tumor area (Fig. 1b). Thus, Magh-
Rh2Cit and Magh-Cit could be considered more efficient in
retaining tumor aggressiveness and inducing its regression
than Rh2Cit. This may be related to the hydrophilicity of
rhodium (II) citrate [20], which increases its dispersion by
the body, especially when the treatments are performed
intravenously.
In our previous study, under the same conditions of tumor
establishment, mice that were intratumorally treated with
2.0 mg/kg (seven injections of 0.28mg/kg each dose) of Rh2Cit
free or associated to NPs (Magh-Rh2Cit) presented a mean
reduction in the tumor volume of 74 and 52 %, respectively
[24]. Thus, in a local application, free rhodium (II) citrate has a
higher antitumor effect than rhodium (II) citrate associated with
NPs. This corroborates the suggestion that the systemic appli-
cation of Rh2Cit resulted in an increase of its dispersion by the
body, probably because of its hydrophilicity [20], and this could
have caused a minor tumor reduction when compared toMagh-
Rh2Cit or Magh-Cit.
Additionally, it is possible that the combination of NPs with
Rh2Cit may have improved the passive targeting of nanoparti-
cles (Magh-Rh2Cit) to the tumor due to the EPR effect in
abnormal tissue, which is characterized by a leaky vasculature
in combination with poor lymphatic drainage around the tumor
[38]. Tumor microvasculature typically contains pores ranging
from 100 to 1000 nm in diameter, while in most healthy tissue,
there are tight intercellular junctions of less than 10 nm [17].
Therefore, the EPR effect may have caused the accumulation of
NPs next to tumor tissues since the hydrodynamic size of the
NPs used in the experiments was 60 nm [21]. This size is greater
than the intercellular gap of the healthy tissue, while it is smaller
than the pores found within the tumor vasculature. Thus, nano-
scale architecture may have selectively targeted Magh-Rh2Cit
and Magh-Cit to the tumor, resulting in higher inhibition of
tumor growth compared to Rh2Cit [17]. Furthermore, neoplastic
cells require higher amounts of micronutrients, such as iron, for
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Fig. 1 Dimensions,
morphometry, and histology of
4T1 tumor tissue sections of the
non-treated and treated groups. a
Tumor volume. b Tumor area
(morphometry). c Percentage of
necrosis area (morphometry). d
Description of coagulation
necrosis. e–h Histopathological
aspects by H&E staining,
showing a central area of necrotic
tissue surrounded by viable tumor
cells in the peripheral areas of
tumors without treatment (control
group, e) and those of the
treatment groups Rh2Cit (f),
Magh-Rh2Cit (g), and Magh-Cit
(h). Pyknotic nuclei (white
arrow). Karyolysis (black arrow).
Karyorrhexis (arrow head).
Bars=0.5 mm
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cell division, possibly leading maghemite NPs to target the
tumor [39]. This could explain the significant differences ob-
served in serum iron of Magh-Rh2Cit and Magh-Cit groups in
relation to healthy animals and control and Rh2Cit (Table 1).
The antineoplastic effect was also showed by the mor-
phometry of the tumors’ necrotic areas, with an increase in
its percentage mean in all treatments (Fig. 1c). Even though
data presented non-significant values compared to the control,
these analyses corroborated tumor volume measurements,
except that Magh-Rh2Cit promoted a higher percentage of
tumor necrosis than Magh-Cit (Fig. 1a, c). This result was
possibly due to the presence of rhodium, which induced a
better antitumor effect. However, the fact that Rh2Cit treat-
ments caused a smaller necrosis area than Magh-Cit might be
related to the greater dispersion of free rhodium through the
body, as described above (Fig. 1e–h).
Furthermore, the antitumor effect of Magh-Cit may be
related to the fact that citric acid is a good antioxidant [40]
and the most effective inhibitor of glycolysis, making it useful
to fight cancer. For this purpose, citrate can be applied as an
inhibitor of the phosphofructokinase enzyme, the pyruvate
dehydrogenase complex, and the succinate dehydrogenase
enzyme of the Krebs cycle, blocking glycolysis and, thus,
resulting in limited metabolism of the mitochondria and low
reproduction capacity of the cell in general [41]. Accordingly,
citric acid has been described as an antineoplastic treatment in
patients with terminal medullary thyroid cancer [42] and
terminal peritoneal mesothelioma [43]. In this context, the
use of Magh-Rh2Cit resulted in the highest mean percentage
of the necrosis area and may have caused a greater antitumor
effect in mice due to three activities: the local rhodium effect,
the NP-mediated drug delivery to the tumor, and the inhibition
of glycolysis by citrate.
Histopathological analyses of the mammary gland and tumors
Histological analysis of the mammary gland of healthy mice
showed peculiar parenchyma and stroma with ducts
surrounded by connective and adipose tissue, and the presence
of a lymph node (Fig. 2a). In the 4T1-bearing mice, the
neoplastic tissues in all groups presented malignant anaplastic
tumors with cells not specialized and distinct from the original
parenchyma (Fig. 2b–i). The fast growth of cancer cells upon
the parenchyma and stroma of breast tissue is related to
Table 1 Effects of Rh2Cit, Magh-Rh2Cit, and Magh-Cit on hematology and biochemical parameters of female Balb/c mice 19 days after animals’
tumor transplantation
Treatments Healthy Control Rh2Cit Magh-Rh2Cit Magh-Cit p-
values
Hematology
RBCs (×106/mm3) 9.61±0.05 9.06±0.15*a 7.55±1.34*a 9.43±0.16 9.47±0.12 0.046
HGB (g/dL) 14.88±0.54 14.62±0.10 12.16±2.31 15.12±0.29 14.46±0.19 0.300
HCT (%) 45.30±0.37 43.58±0.55 35.16±6.23*a 44.44±0.73 44.00±0.50 0.084
MCV (fL) 47.15±0.44 48.17±0.86 46.70±0.34 47.12±0.25 46.50±0.55 0.281
MCH (pg) 15.48±0.49 16.13±0.25 15.72±0.70 16.04±0.09 15.28±0.14*b, d 0.094
MCHC (g/mL) 32.88±1.33 33.57±0.27 33.68±1.73 34.04±0.18 32.88±0.27 0.878
Platelets (×103/mm3) 503.25±53.63 484.50±23.75 393.80±86.04 428.20±74.85 509.20±43.54 0.592
WBC (/mm3) 5193±1688 15,738±4593 18,462±13,158 13,576±2685 14,768±3929 0.249
Lymphocytes (%) 84.25±1.93 8.17±5.27*a 6.00±3.27*a 13.60±10.09*a 4.40±2.68*a 0.035
Neutrophils (%) 12.25±1.65 85.33±4.65*a 90.40±3.31*a 80.40±9.53*a 92.40±2.38*a 0.014
Eosinophils (%) 0.75±0.25 0.33±0.21 0.60±0.25 0.60±0.25 0.20±0.20 0.451
Monocytes (%) 2.75±1.18 6.00±1.81 2.40±0.68 5.20±1.24 2.80±0.37 0.203
Biochemical
ALT (U/L) 32.40±3.04 24.29±2.88 30.20±3.25 23.00±0.89 31.00±2.71 0.087
Creatinine (mg/dL) 0.40±0.00 0.21±0.01*a 0.22±0.02*a 0.20±0.00*a 0.22±0.02*a 0.001
Serum Fe (μg/dL) 180.80±7.37 130.00±7.21*a 133.80±13.43*a 148.40±12.09 161.33±4.59 0.004
Legend: RBC red blood cells, HGB hemoglobin, HCT hematocrit,MCV mean corpuscular volume,MCH mean corpuscular hemoglobin,MCHCmean
corpuscular hemoglobin concentration, WBC white blood cells, ALT alanine transaminase
*Values are represented as mean±standard error (p<0.05)
a Significant compared to the healthy group
b Significant compared to the control group
c Significant compared to the group treated with Magh-Rh2Cit
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morphological changes, such as loss of polarity due to pleo-
morphic cells and a large amount of typical and atypical
mitosis, with three spindle poles, as shown in Fig. 2g. These
features are related to the high malignancy of 4T1 cells, which
were described as an invasive lineage, representing a suitable
model to evaluate the efficacy of anticancer drugs due to its
similarities with metastatic human breast cancer [29].
Tumors were more invasive in the control group (water
administration). This was evidenced by the presence of more
local invasion in the muscle fibers beneath the tumors (Fig. 2b).
A dense inflammatory reaction was seen around tumors in the
Rh2Cit group compared to other groups, corroborating the find-
ings of our previous study [24]. Moreover, various tumor cells
were observed in a process of necrosis with hemorrhagic areas in
tissues of Rh2Cit, Magh-Rh2Cit, and Magh-Cit groups (Fig. 2e,
f, i). Necrotic tissues showed disorganized cellular debris with
indistinct boundaries, pyknotic nuclei, and eosinophilic cyto-
plasm, forming a homogeneous amorphous tissue (Fig. 1d).
Systemic toxicity assessment in mice bearing 4T1 breast
carcinoma
During the whole experimental period (19 days), the in vivo
survival rates of all animals were examined. Deaths started on
experimental day 13 after tumor implantation and occurred until
euthanasia, totalizing nine deaths in all groups with tumor. The
final survival rates of mice were of 100 % in the healthy group,
87.5 % (one death) in the tumor control group, 62.5 % (three
deaths) in the Rh2Cit and Magh-Rh2Cit groups, and 75 % (two
deaths) in the Magh-Cit group (Fig. 3). However, no evident
alterations in clinical parameters were found during the whole
experimental period, which indicated the good tolerance of mice
to treatments. Thus, the survival rates in mice treated with these
formulations should be attributed to the natural invasiveness of
the tumor and not to the treatments themselves.
Values of erythrogram of mice in the control group and
those treated with Rh2Cit, Magh-Rh2Cit, and Magh-Cit
remained similar to those of healthy mice. Still, a significant
reduction in RBC was observed in the control and Rh2Cit
groups and in HCT in the Rh2Cit group (Table 1). However,
although concurrent controls are used as the primary compar-
ison for interpretation of treatment-related changes, compari-
son to reference intervals may also be useful to put hemato-
logical changes in perspective [44]. In this context, we con-
cluded that there were no hematotoxic effects for all experi-
mental groups, since RBC, HCT, and the other variables of the
hemogram remained inside the reference range described for
female mice (6.5–10.1×106/μL for RBC and 32.8–48 % for
Fig. 2 Representative
histopathology of mammary
gland and tumors developed from
Balb/c mice bearing 4T1 breast
carcinoma in non-treated and
treated groups. Tumor slides were
stained with H&E. a Healthy
group. b, cControl. d, eRh2Cit. f,
gMagh-Rh2Cit. h, iMagh-Cit.
Adipocyte (a). Duct (d).
Hemorrhage (h). Lymph node (L).
Muscle fibers (m). Necrosis areas
(n). Tumor (t). Blood vessel (v).
Mitosis (arrow heads).
Infiltration of inflammatory cells
(arrow). Three spindle poles
(large arrow)
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HCT) [45]. The hematological changes could be related to the
development of the tumor, according to these reference
values. This observation is supported by the leukogram data,
whereas there were no significant differences regarding the
WBC, compared to healthy animals.
Generally, in all groups, we observed a significant decrease
in the percentage of lymphocytes with a concomitant increase
in the percentage of neutrophils after tumor implantation
(Table 1), corroborating the results of other studies in our
group [8, 37, 49]. The relative WBC counts have been report-
ed as a non-relevant parameter, as it is the absolute counts that
must be reported and interpreted [46]. Overall, the results
support the finding that there were no hematotoxic effects in
all treatment groups.
Our histopathological analyses of the lung corroborated the
relative WBC counts, showing alveolar wall vessels with an
increase in the number of neutrophils in animals bearing mam-
mary carcinoma (Fig. 4f, i, l, o), while the healthy group
presented a low concentration of leucocytes (Fig. 4c). However,
the rise in WBC was restricted to vessels, with no evident
perivascular infiltration of inflammatory cells, even in animals
treated with Magh-Rh2Cit and Magh-Cit, which presented NPs
inside blood vessels and in perivascular parenchyma (Fig. 4l,
o). Moreover, no foamy cells, pulmonary fibrosis, or presence
of granulomatous lesions were observed in lung tissues of all
treatment groups (Fig. 4). Thus, we concluded that our
nanoformulations were non-toxic, since there was no morpho-
logical change in the lung tissue in all experimental groups.
Along with the hemogram, evaluation of the serum bio-
chemical parameters is crucial for identifying the possible
occurrence of toxicity induced by a new drug, and it must be
correlated with histopathology tests [46]. Thus, serum levels
of ALT were measured to assess possible dysfunctions in the
hepatobiliary system [46, 47] arising from the tumor implan-
tation and/or treatments. Serum creatinine was used as a
kidney function test [46], and the results were compared to
the histopathological analyses of these organs (Fig. 4). ALT is
a cytoplasmic enzyme in which the serum activity is increased
due to leakage across damaged cytoplasmic membranes. In
mice, ALT is found in the highest concentration in the liver,
although its activity has also been demonstrated in the intes-
tine, kidney, heart, muscle, and brain. Despite its widespread
tissue distribution, ALT is widely considered to be a serum
biomarker of hepatocellular injury [46], being used as an
indicator of drug-induced liver hepatotoxicity [48]. In this
study, ALT levels showed no significant statistical differences
(Table 1), as all groups were within the reference values
reported for female Balb/c mice [46].
On the other hand, compared to healthy animals’ liver, we
verified a significantly increased HAI in the control group and
a higher value in the treatment groups (Fig. 4a, d, g, j, m). It
was observed that the untreated animals (control group) had
HAI above 100, indicating that the liver function was irrepa-
rably affected by signs of fibrosis. These changes in the liver,
classified as stage III, prevent the restoration of its functional
structure (Fig. 5b) [34]. For the animals treated with Rh2Cit,
Magh-Rh2Cit, and Magh-Cit, the mean of liver tissue changes
was between 21 and 50, indicating the presence of liver
abnormalities ranging from moderately to heavily damaged
[49] (Fig. 5a).
In the measurements of the hepatocytes, the control group
had significantly increased nucleus area and volume com-
pared to the healthy group, causing liver hypertrophy, but this
was improved by the treatments. Animals treated with Rh2Cit
and Magh-Cit showed a significant reduction in the hepato-
cyte diameter (Table 2). These results could be associated with
the presence of inflammatory infiltrate observed near blood
vessels, mainly close to the NP agglomerations (Fig. 4j, m).
These inflammatory infiltrates, known as inflammatory
pseudotumors (IPTs), are the expression of diverse
Fig. 3 Survival curve for tumor-bearing mice during 19 days of non-
treated and treated groups. Animals received intravenous administration
in tail vein of three doses of 0.5 mg/kg (1.5 mg/kg total dose) rhodium (II)
citrate for Rh2Cit and Magh-Rh2Cit treatments, and the same iron
concentration and nanoparticle amount for Magh-Rh2Cit and Magh-Cit.
Values represent mean values±standard error (n=8/each group). Animals
without tumor and without treatment (healthy) were also included in this
study as negative control group
Fig. 4 Representative histopathology of liver, kidney, and lung from
healthy Balb/c mice and Balb/c mice bearing 4T1 breast carcinoma in
non-treated and treated groups. The animals were treated with the same
Rh2Cit concentration (1.5 mg/kg total dose), and they were euthanized on
the 19th day after tumor inoculation. In general, no morphological
alterations were found in the kidneys and lungs of mice. Increased
neutrophilis were found in all mice bearing mammary carcinoma, and
we also observed nanoparticles in lung tissue of mice treated with Magh-
Rh2Cit and Magh-Cit. Organ sections were stained with H&E. Healthy
mice (a–c) and mice bearing 4T1 breast carcinoma without treatment (d–
f) or treated with Rh2Cit (g–i), Magh-Rh2Cit (j–l), and Magh-Cit (m–o).
Fibrosis (circle). Hepatocyte degeneration (square). Inflammation
(rectangle). Nanoparticles (white arrow). Nucleus degeneration
(pentagon). Pyknotic nuclei (arrow). Vacuolization (arrow head).
Nucleus hypertrophy (white arrow head)
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inflammatory processes that may be accompanied by a tumor-
like mass [50]. The IPTs in the hepatic tissue may suggest that
NPs activate the phagocytic activity to help in removing the
accumulated NPs. Thus, this process could represent a defense
mechanism of detoxification which may be correlated with the
amount of injury to the hepatic tissue [51]. In the untreated
animals (control group), the tumor growth induced irrevers-
ible pathological changes, with no reestablishment of the
functional structure of the liver due to the presence of signs
of fibrosis (Fig. 4d). The histopathological changes in the liver
may therefore have been caused by breast tumor growth,
leading to physiological disorders.
Creatinine is a degradation product of creatine and creatine
phosphate and represents an end product of muscle metabo-
lism. Pathologically, elevated serum creatinine levels can be
caused by prerenal, renal, and postrenal conditions. Prerenal
causes include increased protein catabolism, such as that
which occurs in inflammation or with high-protein diets.
Renal causes are usually associated with conditions that com-
promise 70–75 % of functional renal mass, and postrenal
causes include any cause that results in obstruction of the
lower urinary system [46]. In the present study, the creatinine
levels of all groups of mice bearing breast cancer was signif-
icantly lower compared to healthy mice (Table 1). Thus, we
found no impairment of kidney function by the treatments,
and the change in creatinine levels could be related to the
development of the tumor since a decrease in creatinine levels
has been reported as having no clinical significance [52]. Our
histopathological analyses of the kidneys are supported by this
conclusion, since no morphological alterations in the kidneys
were found (Fig. 4b, e, h, k, n). These data are in agreement
with our previous report with the same formulations when
intratumorally administered [24].
Conclusion
In summary, we demonstrated by intravenous administration
that Magh-Rh2Cit and Magh-Cit promoted a significant
Fig. 5 Histopathological alterations found in the liver of Balb/c mice
bearing 4T1 breast carcinoma in non-treated and treated groups. The
animals were treated with the same Rh2Cit concentration (1.5 mg/kg
total dose), and they were euthanized on the 19th day after tumor
inoculation. Liver sections were stained with H&E. a Alterations were
classified as progressive stages (I, II, and III) for the deterioration of liver
functions. bHistopathological alteration index (HAI) was divided into 0–
10=normal tissue, 11–20=mild to moderate damage to the tissue, 21–
50=moderate to severe damage to the tissue, 51–100=severe damage to
the tissue, and greater than 100=irreparable damage to the tissue. Asterisk
indicates significant differences (*p<0.05)
Table 2 Quantitative parameters of hepatocyte measurements in healthy Balb/c mice and mice bearing 4T1 breast carcinoma without treatment or
treated with Rh2Cit, Magh-Rh2Cit, and Magh-Cit
Groups Healthy Control Rh2Cit Magh-Rh2Cit Magh-Cit
Hepatocyte area (μm2) 84.7±21.1 85.7±7.8 72.3±12.9 83.5±10.4 75.3±12.7
Hepatocyte volume (μm3) 600.3±234.1 599.2±85.8 468.9±129.0 577.5±116.5 497.1±131.0
Cytoplasm area (μm2) 75.6±20.3 72.0±7.6 62.5±11.9 73.4±9.3 66.1±12.0
Cytoplasm volume (μm3) 508.2±201.4 462.0±73.0 376.9±105.0 476.3±91.6 409.9±109.5
Cytoplasmic/nuclear ratio (μm2) 8.3±1.6 5.2±1.7 6.32±2 7.2±1.8 7.2±1.1
Nucleus area (μm2) 9.0±1.6 13.7±1.7*a 9.8±2.0*b 10.0±1.8*b 9.1±1.1*b
Diameter of nucleus (μm) 3.7±0.2 4.1±0.4 4.0±0.3 4.0±0.3 3.9±0.3
Nucleus volume (μm3) 20.8±5.3 38.3±7.3*a 23.7±7.6*b 24.3±6.7*b 20.9±3.8*b
Letters indicate significant differences in 2-by-2 comparisons detected by the Tukey test, with a=significant compared to the healthy group and b=
significant compared to the control group. Results are expressed as mean±SE of the mean
*p<0.05
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decrease in tumor area and did not induce toxicity effects in
tested experimental conditions. No studies about the systemic
action of rhodium (II) citrate-loaded maghemite nanoparticles
have been carried out, making this report a suitable starting
point for exploring the therapeutic potential of these com-
pounds in treating breast cancer.
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